

David A Fox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2505060/publications.pdf>

Version: 2024-02-01

160
papers

11,758
citations

30070

54
h-index

30087

103
g-index

164
all docs

164
docs citations

164
times ranked

13106
citing authors

#	ARTICLE	IF	CITATIONS
1	An alternative pathway of T-cell activation: A functional role for the 50 kd T11 sheep erythrocyte receptor protein. <i>Cell</i> , 1984, 36, 897-906.	28.9	1,153
2	NETs Are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis. <i>Science Translational Medicine</i> , 2013, 5, 178ra40.	12.4	1,016
3	Th17 cells in human disease. <i>Immunological Reviews</i> , 2008, 223, 87-113.	6.0	960
4	Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 1985, 312, 818-822.	27.0	833
5	In Vivo Activated T Lymphocytes in the Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis. <i>New England Journal of Medicine</i> , 1985, 312, 1405-1411.	27.0	310
6	Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 1988, 318, 1423-1431.	27.0	288
7	The role of T cells in the immunopathogenesis of rheumatoid arthritis. New perspectives. <i>Arthritis and Rheumatism</i> , 1997, 40, 598-609.	6.7	269
8	Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis. <i>Science Immunology</i> , 2017, 2, .	11.9	228
9	Cells of the synovium in rheumatoid arthritis. T lymphocytes. <i>Arthritis Research and Therapy</i> , 2007, 9, 202.	3.5	191
10	Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. <i>Journal of Clinical Investigation</i> , 2001, 107, 1275-1284.	8.2	180
11	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase \ll Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163
12	Advances in the Medical Treatment of Rheumatoid Arthritis. <i>Hand Clinics</i> , 2011, 27, 11-20.	1.0	138
13	Top3 $\hat{2}$ is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. <i>Nature Neuroscience</i> , 2013, 16, 1238-1247.	14.8	124
14	The functional interactions between CD98, $\hat{2}1$ -integrins, and CD147 in the induction of U937 homotypic aggregation. <i>Blood</i> , 2001, 98, 374-382.	1.4	119
15	TLRs, future potential therapeutic targets for RA. <i>Autoimmunity Reviews</i> , 2017, 16, 103-113.	5.8	118
16	Synovial biology and T cells in rheumatoid arthritis. <i>Pathophysiology</i> , 2005, 12, 183-189.	2.2	116
17	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 2451-2464.	8.2	106
18	Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF- \hat{z} Inhibition for Cancer and Autoimmune Disease. <i>Cell Chemical Biology</i> , 2017, 24, 1029-1039.e7.	5.2	104

#	ARTICLE	IF	CITATIONS
19	Effector Function of Resting T Cells: Activation of Synovial Fibroblasts. <i>Journal of Immunology</i> , 2001, 166, 2270-2275.	0.8	102
20	Effectiveness of rheumatoid hand surgery: Contrasting perceptions of hand surgeons and rheumatologists. <i>Journal of Hand Surgery</i> , 2003, 28, 3-11.	1.6	98
21	Neutrophil extracellular traps mediate articular cartilage damage and enhance cartilage component immunogenicity in rheumatoid arthritis. <i>JCI Insight</i> , 2020, 5, .	5.0	97
22	Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. <i>Blood</i> , 2014, 123, 786-793.	1.4	94
23	Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factor Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 349, 480-486.	2.5	92
24	UM4D4+ (CDw60) T Cells Are Compartmentalized into Psoriatic Skin and Release Lymphokines That Induce a Keratinocyte Phenotype Expressed in Psoriatic Lesions. <i>Journal of Investigative Dermatology</i> , 1990, 95, 275-282.	0.7	91
25	Synovial cellular and molecular markers in rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 2017, 39, 385-393.	6.1	89
26	Presentation of arthritogenic peptide to antigen-specific T cells by fibroblast-like synoviocytes. <i>Arthritis and Rheumatism</i> , 2007, 56, 1497-1506.	6.7	88
27	Membrane-Type I Matrix Metalloproteinase-Dependent Regulation of Rheumatoid Arthritis Synoviocyte Function. <i>Journal of Immunology</i> , 2010, 184, 6396-6406.	0.8	87
28	Effects of administration of an anti-cd5 plus immunoconjugate in rheumatoid arthritis. results of two phase ii studies. <i>Arthritis and Rheumatism</i> , 1993, 36, 620-630.	6.7	86
29	T-Lymphocyte Clones Initiated from Lesional Psoriatic Skin Release Growth Factors that Induce Keratinocyte Proliferation. <i>Journal of Investigative Dermatology</i> , 1993, 101, 695-700.	0.7	86
30	T cell subsets and their role in the pathogenesis of rheumatic disease. <i>Current Opinion in Rheumatology</i> , 2014, 26, 204-210.	4.3	85
31	Abnormalities in CD4+ T-lymphocyte subsets in inflammatory rheumatic diseases. <i>American Journal of Medicine</i> , 1988, 84, 817-825.	1.5	84
32	Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R128.	3.5	78
33	Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3695-3702.	7.1	77
34	Regulation of pathogenic IL-17 responses in collagen-induced arthritis: roles of endogenous interferon-gamma and IL-4. <i>Arthritis Research and Therapy</i> , 2009, 11, R158.	3.5	76
35	The role of T helper type 17 cells in inflammatory arthritis. <i>Clinical and Experimental Immunology</i> , 2010, 159, 225-237.	2.6	75
36	DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. <i>Nature Communications</i> , 2017, 8, 14252.	12.8	75

#	ARTICLE	IF	CITATIONS
37	Validity and responsiveness of the Michigan hand questionnaire in patients with rheumatoid arthritis: A multicenter, international study. <i>Arthritis Care and Research</i> , 2010, 62, 1569-1577.	3.4	74
38	Endothelial dysfunction in rat adjuvant-induced arthritis: Vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. <i>Arthritis and Rheumatism</i> , 2006, 54, 1847-1855.	6.7	73
39	Targeting IL-17 and Th17 Cells in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 345-366.	1.9	71
40	A Multicenter Clinical Trial in Rheumatoid Arthritis Comparing Silicone Metacarpophalangeal Joint Arthroplasty With Medical Treatment. <i>Journal of Hand Surgery</i> , 2009, 34, 815-823.	1.6	70
41	CD6 as a potential target for treating multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2687-2692.	7.1	70
42	Human B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand and Secrete MHCII+FasL+ Killer Exosomes. <i>Frontiers in Immunology</i> , 2014, 5, 144.	4.8	69
43	Sensitivity and Resistance to Regulation by IL-4 during Th17 Maturation. <i>Journal of Immunology</i> , 2011, 187, 4440-4450.	0.8	68
44	CD318 is a ligand for CD6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6912-E6921.	7.1	67
45	Cytokine Blockade as a New Strategy to Treat Rheumatoid Arthritis. <i>Archives of Internal Medicine</i> , 2000, 160, 437.	3.8	66
46	Cell-cell Interactions in Rheumatoid Arthritis Synovium. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 311-323.	1.9	66
47	Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 1827-1835.	6.7	64
48	Historical Perspective on the Etiology of Rheumatoid Arthritis. <i>Hand Clinics</i> , 2011, 27, 1-10.	1.0	63
49	Responsiveness of human T lymphocytes to bacterial superantigens presented by cultured rheumatoid arthritis synoviocytes. <i>Arthritis and Rheumatism</i> , 1996, 39, 125-136.	6.7	62
50	Molecular Interactions between T Cells and Fibroblast-Like Synoviocytes. <i>American Journal of Pathology</i> , 2007, 171, 1588-1598.	3.8	62
51	Interactions of T Cells with Fibroblast-Like Synoviocytes: Role of the B7 Family Costimulatory Ligand B7-H3. <i>Journal of Immunology</i> , 2008, 180, 2989-2998.	0.8	62
52	Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors. <i>Arthritis and Rheumatology</i> , 2016, 68, 2975-2985.	5.6	62
53	Activation of human T cells through CD6: functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein. <i>International Immunology</i> , 1993, 5, 783-792.	4.0	61
54	Immunocompetent Properties of Human Osteoblasts: Interactions With T Lymphocytes. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 29-36.	2.8	58

#	ARTICLE	IF	CITATIONS
55	CD6: expression during development, apoptosis and selection of human and mouse thymocytes. <i>International Immunology</i> , 2002, 14, 585-597.	4.0	56
56	The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases. <i>Clinical Immunology</i> , 2017, 175, 10-15.	3.2	52
57	IL-11 facilitates a novel connection between RA joint fibroblasts and endothelial cells. <i>Angiogenesis</i> , 2018, 21, 215-228.	7.2	52
58	Establishing clinical severity for PROMISÂ® measures in adult patients with rheumatic diseases. <i>Quality of Life Research</i> , 2018, 27, 755-764.	3.1	52
59	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
60	Novel molecular mechanisms of dendritic cell-induced T cell activation. <i>International Immunology</i> , 2000, 12, 1051-1061.	4.0	50
61	Systemic Toxicity Following Administration of Sirolimus (Formerly Rapamycin) for Psoriasis. <i>Archives of Dermatology</i> , 1999, 135, 553-7.	1.4	49
62	Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: Effect of angiotensin receptor blockers. <i>Arthritis and Rheumatism</i> , 2010, 62, 1319-1328.	6.7	49
63	Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis. <i>Science Advances</i> , 2020, 6, .	10.3	49
64	Interleukin-17 as a molecular target in immune-mediated arthritis: Immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. <i>Arthritis and Rheumatism</i> , 2007, 56, 89-100.	6.7	48
65	Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. <i>Arthritis and Rheumatism</i> , 2013, 65, 618-626.	6.7	48
66	Loss of SH3 Domain-Binding Protein 2 Function Suppresses Bone Destruction in Tumor Necrosis Factor-Driven and Collagen-Induced Arthritis in Mice. <i>Arthritis and Rheumatology</i> , 2015, 67, 656-667.	5.6	48
67	CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders. <i>Journal of Immunology</i> , 2020, 204, 3-11.	0.8	48
68	Long-term followup for rheumatoid arthritis patients in a multicenter outcomes study of silicone metacarpophalangeal joint arthroplasty. <i>Arthritis Care and Research</i> , 2012, 64, 1292-1300.	3.4	45
69	Macrophages are the primary effector cells in IL-7-induced arthritis. <i>Cellular and Molecular Immunology</i> , 2020, 17, 728-740.	10.5	45
70	Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 841-854.	5.6	44
71	Regulatory T cell defects in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 710-713.	6.7	43
72	Pharmacokinetic optimization of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1744-1749.	2.2	42

#	ARTICLE	IF	CITATIONS
73	Role of Complement in a Rat Model of Paclitaxel-Induced Peripheral Neuropathy. <i>Journal of Immunology</i> , 2018, 200, 4094-4101.	0.8	42
74	Surgical management of the rheumatoid hand: consensus and controversy among rheumatologists and hand surgeons. <i>Journal of Rheumatology</i> , 2003, 30, 1464-72.	2.0	41
75	Interleukin-5 Supports the Expansion of Fas Ligand-Expressing Killer B Cells that Induce Antigen-Specific Apoptosis of CD4+ T Cells and Secrete Interleukin-10. <i>PLoS ONE</i> , 2013, 8, e70131.	2.5	39
76	A unique role for galectin-9 in angiogenesis and inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 31.	3.5	39
77	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. <i>Vaccine</i> , 2021, 39, 6111-6116.	3.8	39
78	Killer B Lymphocytes and Their Fas Ligand Positive Exosomes as Inducers of Immune Tolerance. <i>Frontiers in Immunology</i> , 2015, 6, 122.	4.8	38
79	Expression and Function of Aminopeptidase N/CD13 Produced by Fibroblast-like Synoviocytes in Rheumatoid Arthritis: Role of CD13 in Chemotaxis of Cytokine-Activated T Cells Independent of Enzymatic Activity. <i>Arthritis and Rheumatology</i> , 2015, 67, 74-85.	5.6	38
80	Expression and Characterization of a Novel CD6 Ligand in Cells Derived from Joint and Epithelial Tissues. <i>Journal of Immunology</i> , 2004, 173, 6125-6133.	0.8	36
81	CD19+CD5+ B Cells in Primary IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2130-2139.	6.1	36
82	Outcomes of Silicone Arthroplasty for Rheumatoid Metacarpophalangeal Joints Stratified by Fingers. <i>Journal of Hand Surgery</i> , 2009, 34, 1647-1652.	1.6	36
83	Cell cycle progression is associated with distinct patterns of phosphorylation of Op18. <i>Biochemical and Biophysical Research Communications</i> , 1992, 185, 197-203.	2.1	35
84	Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional Consequences. <i>Journal of Biological Chemistry</i> , 2008, 283, 21179-21186.	3.4	35
85	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4350-4369.	6.4	34
86	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
87	Phospholipase D enzymes facilitate IL-17- and TNF±-induced expression of proinflammatory genes in rheumatoid arthritis synovial fibroblasts (RASf). <i>Immunology Letters</i> , 2016, 174, 9-18.	2.5	33
88	Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. <i>Arthritis Research and Therapy</i> , 2019, 21, 292.	3.5	31
89	IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2199-2210.	10.5	31
90	Defective CD2 pathway T cell activation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1991, 34, 561-571.	6.7	28

#	ARTICLE	IF	CITATIONS
91	Leukemic T Cells from Patients with Cutaneous T-Cell Lymphoma Demonstrate Enhanced Activation Through CDw60, CD2, and CD28 Relative to Activation Through the T-Cell Antigen Receptor Complex. <i>Journal of Investigative Dermatology</i> , 1993, 100, 667-673.	0.7	28
92	Clinical and experimental evidence for targeting CD6 in immune-based disorders. <i>Autoimmunity Reviews</i> , 2018, 17, 493-503.	5.8	28
93	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 92-100.	4.9	28
94	Biological therapies: A novel approach to the treatment of autoimmune disease. <i>American Journal of Medicine</i> , 1995, 99, 82-88.	1.5	27
95	A Prospective Study Comparing Outcomes after Reconstruction in Rheumatoid Arthritis Patients with Severe Ulnar Drift Deformities. <i>Plastic and Reconstructive Surgery</i> , 2009, 123, 1769-1777.	1.4	27
96	Kinase Inhibition "A New Approach to the Treatment of Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2012, 367, 565-567.	27.0	27
97	The roles of IFN- γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. <i>Modern Rheumatology</i> , 2013, 23, 1140-1150.	1.8	27
98	Targeting CD6 for the treatment of experimental autoimmune uveitis. <i>Journal of Autoimmunity</i> , 2018, 90, 84-93.	6.5	27
99	Etanercept-associated Pulmonary Granulomatous Inflammation in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 2279.2-2282.	2.0	25
100	Variation in Rheumatoid Hand and Wrist Surgery among Medicare Beneficiaries: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 429-436.	2.0	25
101	The Human 4F2 Antigen: Evidence for Cryptic and Noncryptic Epitopes and for a Role of 4F2 in Human T Lymphocyte Activation. <i>Cellular Immunology</i> , 1994, 154, 253-263.	3.0	24
102	A polymorphism in the interleukin-4 receptor affects the ability of interleukin-4 to regulate Th17 cells: a possible immunoregulatory mechanism for genetic control of the severity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R15.	3.5	24
103	Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?. <i>Clinical and Translational Science</i> , 2010, 3, 319-326.	3.1	23
104	Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 3153-3162.	0.7	23
105	Inflammatory properties of inhibitor of DNA binding 1 secreted by synovial fibroblasts in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 87.	3.5	23
106	CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on β -interferon activated keratinocytes. <i>Immunology Letters</i> , 1997, 58, 9-14.	2.5	22
107	Evidence for the expression of a second CD6 ligand by synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2000, 43, 329.	6.7	22
108	High-Throughput Profiling of Ion Channel Activity in Primary Human Lymphocytes. <i>Analytical Chemistry</i> , 2008, 80, 3728-3735.	6.5	22

#	ARTICLE	IF	CITATIONS
109	Patient expectations and long-term outcomes in rheumatoid arthritis patients: results from the SARA (Silicone Arthroplasty in Rheumatoid Arthritis) study. <i>Clinical Rheumatology</i> , 2015, 34, 641-651.	2.2	22
110	Seven-Year Outcomes of the Silicone Arthroplasty in Rheumatoid Arthritis Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2017, 69, 973-981.	3.4	22
111	The roles of IFN- γ versus IL-17 in pathogenic effects of human Th17 cells on synovial fibroblasts. <i>Modern Rheumatology</i> , 2013, 23, 1140-50.	1.8	22
112	The Incidence of Upper and Lower Extremity Surgery for Rheumatoid Arthritis Among Medicare Beneficiaries. <i>Journal of Bone and Joint Surgery - Series A</i> , 2015, 97, 403-410.	3.0	21
113	SH3BP2 Gain-Of-Function Mutation Exacerbates Inflammation and Bone Loss in a Murine Collagen-Induced Arthritis Model. <i>PLoS ONE</i> , 2014, 9, e105518.	2.5	20
114	Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. <i>Arthritis Research and Therapy</i> , 2014, 16, 411.	3.5	20
115	Co-stimulation and T cells as therapeutic targets. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 463-477.	3.3	19
116	Citrullination: A Specific Target for the Autoimmune Response in Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2015, 195, 5-7.	0.8	18
117	CD6 is a target for cancer immunotherapy. <i>JCI Insight</i> , 2021, 6, .	5.0	18
118	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 10.	3.5	18
119	Localization, Shedding, Regulation and Function of Aminopeptidase N/CD13 on Fibroblast like Synoviocytes. <i>PLoS ONE</i> , 2016, 11, e0162008.	2.5	18
120	Transforming growth factor β 2 activated kinase 1: a potential therapeutic target for rheumatic diseases. <i>Rheumatology</i> , 2017, 56, kew301.	1.9	17
121	Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 228-236.	3.4	17
122	Interferon-stimulated GTPases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (GBP) family. <i>Rheumatology</i> , 2021, 60, 494-506.	1.9	17
123	Fine Mapping of Monoclonal Antibody Epitopes on Human von Willebrand Factor Using a Recombinant Peptide Library. <i>Thrombosis and Haemostasis</i> , 1992, 67, 166-171.	3.4	17
124	Real time visualization of cancer cell death, survival and proliferation using fluorochrome-transfected cells in an IncuCyte [®] imaging system. <i>Journal of Biological Methods</i> , 2020, 7, e133.	0.6	17
125	Immediate hypersensitivity reaction to cyclophosphamide. <i>Arthritis and Rheumatism</i> , 1994, 37, 1101-1104.	6.7	16
126	Cytokine production by dendritic cells genetically engineered to express IL-4: induction of Th2 responses and differential regulation of IL-12 and IL-23 synthesis. <i>Journal of Gene Medicine</i> , 2005, 7, 869-877.	2.8	15

#	ARTICLE	IF	CITATIONS
127	Attenuation of Murine Collagen-Induced Arthritis by Targeting α CD6. Arthritis and Rheumatology, 2020, 72, 1505-1513.	5.6	15
128	Secondary immune amplification following live poliovirus immunization in humans. Clinical Immunology and Immunopathology, 1987, 44, 321-328.	2.0	11
129	An Anti-CD2 Monoclonal Antibody That Both Inhibits and Stimulates T Cell Activation Recognizes a Subregion of CD2 Distinct from Known Ligand-Binding Sites. Cellular Immunology, 1993, 150, 235-246.	3.0	11
130	Angiogenic and Arthritogenic Properties of the Soluble Form of CD13. Journal of Immunology, 2019, 203, 360-369.	0.8	11
131	Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight, 2022, 7, .	5.0	11
132	Activation of human T cell clones through the UM4D4/CDw60 surface antigen. Cellular Immunology, 1990, 128, 480-489.	3.0	10
133	Regulatory T cells in rheumatoid arthritis. Current Rheumatology Reports, 2008, 10, 405-412.	4.7	10
134	The Effect of Swan Neck and Boutonniere Deformities on the Outcome of Silicone Metacarpophalangeal Joint Arthroplasty in Rheumatoid Arthritis. Plastic and Reconstructive Surgery, 2013, 132, 597-603.	1.4	9
135	Differences between the United States and the United Kingdom in the treatment of rheumatoid arthritis: analyses from a hand arthroplasty trial. Clinical Rheumatology, 2010, 29, 363-367.	2.2	8
136	Regulation of Th17 Maturation by Interleukin 4. Critical Reviews in Immunology, 2013, 33, 379-387.	0.5	7
137	Noxa in rheumatic diseases: present understanding and future impact. Rheumatology, 2014, 53, 1539-1546.	1.9	7
138	Rheumatoid Arthritis—Heresies and Speculations. Perspectives in Biology and Medicine, 1997, 40, 479-491.	0.5	6
139	Absence of complement component 3 does not prevent classical pathway-mediated hemolysis. Blood Advances, 2019, 3, 1808-1814.	5.2	6
140	Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1. Journal of Clinical Investigation, 2022, 132, .	8.2	6
141	Reflecting on Early Arthritis. Journal of Rheumatology, 2012, 39, 2059-2061.	2.0	5
142	Response to comment on "Synovial fibroblast-neutrophil interactions promote pathogenic adaptive immunity in rheumatoid arthritis". Science Immunology, 2018, 3, .	11.9	5
143	Editorial: Immunomodulatory Functions of Fibroblast-like Synoviocytes in Joint Inflammation and Destruction during Rheumatoid Arthritis. Frontiers in Immunology, 2020, 11, 955.	4.8	5
144	Citrullinated Inhibitor of α DNA Binding 1 Is a Novel Autoantigen in Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1241-1251.	5.6	4

#	ARTICLE	IF	CITATIONS
145	Mouse CD6: sequence of cDNA and expression of mRNA. Immunology Letters, 1996, 49, 133-137.	2.5	3
146	Interactions between T cells and synovial fibroblasts. Modern Rheumatology, 2000, 10, 16-18.	1.8	3
147	The role of CD6 in autoimmune diseases. Cellular and Molecular Immunology, 2018, 15, 1001-1002.	10.5	3
148	Xenogeneic cells and superantigen induce human T-cell activation in the absence of T-cell recognition of xenoantigen. Translational Research, 2003, 142, 149-157.	2.3	1
149	Unity in the field of rheumatology: The role of the ACR. Arthritis and Rheumatism, 2009, 60, 313-316.	6.7	1
150	Treatment for Rheumatic Disorders. New England Journal of Medicine, 2006, 354, 1322-1323.	27.0	0
151	The past and the future of Arthritis & Rheumatism: A view from the American College of Rheumatology. Arthritis and Rheumatism, 2008, 58, S7-S10.	6.7	0
152	The future of ILAR. Clinical Rheumatology, 2009, 28, 493-494.	2.2	0
153	Preface. Rheumatic Disease Clinics of North America, 2010, 36, xiii-xiv.	1.9	0
154	Treg cells to the rescue. Arthritis and Rheumatism, 2012, 64, 2426-2428.	6.7	0
155	Current and future approaches to the treatment of immunologic diseases: new targets and new therapeutic agents. Translational Research, 2015, 165, 251-254.	5.0	0
156	C3 as a potential target for treating complement-mediated hemolysis. Molecular Immunology, 2018, 102, 183.	2.2	0
157	Divergence of the systemic immune response following oral infection with distinct strains of Porphyromonas gingivalis. Molecular Oral Microbiology, 2012, , n/a-n/a.	2.7	0
158	Modulating myofibroblast transition in systemic sclerosis through inhibition of Rho/MRTF regulated transcription (1054.9). FASEB Journal, 2014, 28, 1054.9.	0.5	0
159	CD6-Targeted Antibody-Drug Conjugate As a Potential Therapeutic Agent for T Cell Lymphomas. Blood, 2021, 138, 1193-1193.	1.4	0
160	A CD6-Targeted Antibody-Drug Conjugate As a Potential Therapy for T Cell-Mediated Disorders. Blood, 2021, 138, 3817-3817.	1.4	0